Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions,Annals of Oncology

当前位置： X-MOL 学术 › Ann. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-07-19 , DOI: 10.1093/annonc/mdx288
C. Mayo-de-las-Casas , N. Jordana-Ariza , M. Garzón-Ibañez , A. Balada-Bel , J. Bertrán-Alamillo , S. Viteri-Ramírez , N. Reguart , M.A. Muñoz-Quintana , P. Lianes-Barragan , C. Camps , E. Jantús , J. Remon-Massip , S. Calabuig , D. Aguiar , M.L. Gil , N. Viñolas , A.K. Santos-Rodríguez , M. Majem , B. García-Peláez , S. Villatoro , A. Pérez-Rosado , J.C. Monasterio , E. Ovalle , M.J. Catalán , R. Campos , D. Morales-Espinosa , A. Martínez-Bueno , M. González-Cao , X. González , I. Moya-Horno , A.E. Sosa , N. Karachaliou , R. Rosell , M.A. Molina-Vila

In a significant percentage of advanced non-small-cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses. We prospectively analyzed if circulating-free DNA (cfDNA) purified from blood can be used as a surrogate in this setting to select patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

中文翻译：

大规模，前瞻性筛查晚期NSCLC患者血液中的EGFR突变，以指导治疗决策

在相当多的晚期非小细胞肺癌（NSCLC）患者中，肿瘤组织无法获得或不足以进行基因分析。我们前瞻性地分析了从血液中纯化的无循环DNA（cfDNA）是否可以用作这种情况下的替代药物，以选择使用表皮生长因子受体酪氨酸激酶抑制剂（EGFR -TKIs）进行治疗的患者。

更新日期：2017-09-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11